Ketamine drugmakers seek FDA approval as providers raise concerns: 5 things to know
Ella Ruder | October 21, 2026
More than a dozen companies are racing to win FDA approval for ketamine-based mental health treatments. Providers warn that one company’s bid could sharply raise the cost of the generic drug, while most of the new products are designed to skip the talk therapy many clinicians consider essential, The New York Times reported Oct. 20. The companies are developing new formulations and combinations of ketamine, a generic anesthetic increasingly used off-label for depression and other mental health conditions. Johnson & Johnson’s Spravato, a ketamine-like nasal spray, is the only FDA-approved… Originally published in Becker’s Hospital Review. Read More
Recent Posts
Seniors Left Waiting as Treatment Bill Faces Uphill Climb
Ashleigh Hollowell | October 22, 2026
Shifting Accountability from Effort to Achievement: The Potential Impact of the ABA Toolkit
Chris Larson | October 22, 2026
Acute Onset of Mood and Psychotic Symptoms After Rapid Discontinuation of a GLP-1 Agonist
Journal of Clinical Psychiatry | October 22, 2026
Bound for Calmness: Voluntary Rope-Tying Behavior in Late-Life Generalized Anxiety Disorder
Journal of Clinical Psychiatry | October 22, 2026
Apogem Capital Leads Minority Investment in Family Care Center
Laura Lovett | October 21, 2026
Integrated Psychiatric Consultants
Office Hours:Mon-Fri, 9 a.m. - 5 p.m. CT